Clinical Trials Logo

Mycetoma clinical trials

View clinical trials related to Mycetoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04401969 Completed - Mycetoma Clinical Trials

Tissue Microenvironment Signatures of the Mycetoma Granuloma

Start date: March 7, 2019
Phase:
Study type: Observational

Mycetoma is the most neglected of the neglected tropical diseases. It is caused by certain fungi or bacteria. It is endemic in many tropical and subtropical regions and Sudan seems to be the mycetoma homeland. This chronic subcutaneous destructive and disabling inflammatory disease has many serious medical and socio-economic impacts on patients, community and health authorities. This work may suggest new therapeutic options for mycetoma that target the inflammatory pathogenic pathway and hence help in designing universal treatment options for mycetoma patients. Two overlapping aims were investigated in this project to advance our overall goals: 1. Profiling the immune/inflammatory signatures in the tissue microenvironment of fungus-induced mycetoma lesions 2. Profiling the immune/inflammatory signatures in the tissue microenvironment of bacteria-induced mycetoma lesions.

NCT ID: NCT03086226 Recruiting - Mycetoma Clinical Trials

Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan

Start date: April 30, 2017
Phase: Phase 2
Study type: Interventional

This study is a single-center, comparative, randomized, double-blind, parallel-group, active-controlled, clinical superiority trial of Fosravuconazole versus Itraconazole combined with surgery in subjects with eumycetoma in Sudan. There will be three arms in this study: The first arm will be Fosravuconazole 300 mg weekly, the second arm will have Fosravuconazole 200 mg weekly and the control arm is the standard treatment using itraconazole 400mg daily. At 3 months time-point, interim analysis will be done and one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity.